The GALILEO trial has been stopped after an early look at outcomes revealed rivaroxaban was associated with greater odds of thromboembolic events, all-cause death and bleeding events compared to antiplatelet therapy following transcatheter aortic valve replacement (TAVR).

A report published in Circulation: Cardiovascular Quality and Outcomes found a faith-based program in traditionally black churches was able to lower systolic blood pressure among attendants by an average 5.8 mm Hg—a result that more typical public education programs failed to replicate.

Patients who experience ischemic stroke in the posterior circulation are at greater risk of impaired functional outcomes compared to those with anterior circulation stroke (ACS)—particularly if their time to hospital arrival exceeds 4.5 hours, according to an Austrian registry study published Oct. 8 in Stroke.

Digoxin, a cardiac glycoside popularly sold under the brand name Lanoxin, poses a major threat to the heart health of atrial fibrillation (AF) and heart failure (HF) patients, according to a review published in the American Journal of Cardiology Oct. 4. Even without confounding conditions, the drug can raise an individual’s risk of all-cause mortality.

Half of women and a third of men will be diagnosed with stroke, dementia or parkinsonism in their lifetime, according to a nearly three-decades-long study of neurological disease in the Dutch population. Up to 50 percent of those cases, though, might be mitigated with early prevention.

Forearm blood flow is preserved two decades after coronary artery bypass graft (CABG) surgery using radial artery grafts, Australian researchers reported in a letter published in the Journal of the American College of Cardiology.

The deal Regeneron and Sanofi cut with Express Scripts to lower the prices of their PCSK9 inhibitor in exchange for simpler preauthorization forms has opened the floodgates for another two dozen such deals for the cholesterol-lowering drug class, the New York Times reported.

IRVINE, Calif., Oct. 8, 2018 — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that it has commenced the U.S. pivotal trial that will study its self-expanding CENTERA transcatheter valve for severe, symptomatic aortic stenosis (AS) patients at intermediate risk of open-heart surgery.

As an adjunct to standard treatment for patients with type 2 diabetes, liraglutide appears at least as protective against cardiovascular events for patients with chronic kidney disease (CKD) as for those without CKD, according to a subgroup analysis of the LEADER trial published in Circulation.

Women who experience menopause before age 40 are twice as likely to develop type 2 diabetes (T2D) than those who reach menopause at a more normal age, according to research presented at the European Association for the Study of Diabetes’ annual conference in Berlin last week.